Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eciruciclib (BPI-1178) in Advanced Solid Tumors and HR+/HER2- Breast Cancer
NCT04282031Phase 2Recruiting
- Sponsor
- Beta Pharma
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eciruciclib in solid tumor (advanced stage) and breast cancer (3 arms), sponsored by Beta Pharma. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
eciruciclib
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT04282031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282031.